Regan M - Search Results

1

Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy.

Signoretti S, Regan M, Atkins M. Signoretti S, et al. Among authors: regan m. BJU Int. 2008 Jun;101 Suppl 4:31-5. doi: 10.1111/j.1464-410X.2008.07646.x. BJU Int. 2008. PMID: 18430120 Review. No abstract available.

2

Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.

Atkins MB, Regan M, McDermott D. Atkins MB, et al. Among authors: regan m. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6342S-6S. doi: 10.1158/1078-0432.CCR-040029. Clin Cancer Res. 2004. PMID: 15448028 Review.

3

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB. McDermott DF, et al. Among authors: regan mm. J Clin Oncol. 2005 Jan 1;23(1):133-41. doi: 10.1200/JCO.2005.03.206. J Clin Oncol. 2005. PMID: 15625368 Clinical Trial.

4

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S. Atkins M, et al. Among authors: regan m. Clin Cancer Res. 2005 May 15;11(10):3714-21. doi: 10.1158/1078-0432.CCR-04-2019. Clin Cancer Res. 2005. PMID: 15897568

5

Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.

Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, Oh WK. Nakabayashi M, et al. Among authors: regan mm. BJU Int. 2005 Oct;96(6):783-6. doi: 10.1111/j.1464-410X.2005.05714.x. BJU Int. 2005. PMID: 16153200

6

Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models.

Hines-Peralta A, Sukhatme V, Regan M, Signoretti S, Liu ZJ, Goldberg SN. Hines-Peralta A, et al. Among authors: regan m. Radiology. 2006 Jul;240(1):82-9. doi: 10.1148/radiol.2401050788. Epub 2006 May 23. Radiology. 2006. PMID: 16720872

7

Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.

McDermott DF, Regan MM, Atkins MB. McDermott DF, et al. Among authors: regan mm. Clin Genitourin Cancer. 2006 Sep;5(2):114-9. doi: 10.3816/CGC.2006.n.027. Clin Genitourin Cancer. 2006. PMID: 17026799 Review.

8

The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer.

Cho D, Signoretti S, Regan M, Mier JW, Atkins MB. Cho D, et al. Among authors: regan m. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):758s-763s. doi: 10.1158/1078-0432.CCR-06-1986. Clin Cancer Res. 2007. PMID: 17255306 Review.

9

Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice.

Hakimé A, Hines-Peralta A, Peddi H, Atkins MB, Sukhatme VP, Signoretti S, Regan M, Goldberg SN. Hakimé A, et al. Among authors: regan m. Radiology. 2007 Aug;244(2):464-70. doi: 10.1148/radiol.2442061005. Radiology. 2007. PMID: 17641366

10

Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.

Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E, Atkins M. Cho D, et al. Among authors: regan m. Clin Genitourin Cancer. 2007 Sep;5(6):379-85. doi: 10.3816/CGC.2007.n.020. Clin Genitourin Cancer. 2007. PMID: 17956710

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

856 results

Search Page

Filters